Hauser et al. [18] showed that RASSF1A is methylated in 22.9% of patients; the study of De Martino et al. [19] demonstrated methylation of RASSF1A in 45.9% of patients; Hoque et al. [20] observed methylation of this gene in 11% of serum samples of patients with RCC. This evidence concerns the gene RASSF1 and renal cell carcinoma.